SCHEMBL3535945

SCHEMBL3535945

Cc1occ(C(=O)NS(=O)(=O)c2ccccc2)c1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.52
HPGD P15428 1/20 0.51
EGFR P00533 1/20 0.50
FLT1 P17948 3/20 0.47
FLT4 P35916 3/20 0.47
KDR P35968 3/20 0.47
POLB P06746 1/20 0.47
PTGS2 P35354 4/20 0.46
PTGS1 P23219 2/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
P4HTM Q9NXG6 2/20 0.43
ALKBH2 Q6NS38 1/20 0.42
ALKBH5 Q6P6C2 1/20 0.42
FTO Q9C0B1 1/20 0.42
BCAT1 P54687 1/20 0.42
PTGER4 P35408 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL653805 0.74 FLT1 (0.77) KDM4EHPGDEGFRFLT1FLT4
SCHEMBL10765828 0.74 KDM4E (0.72) KDM4EHPGDEGFRFLT1FLT4
SCHEMBL7318528 0.72 PTGS2 (0.57) KDM4EHPGDEGFRFLT1FLT4
SCHEMBL3535940 0.72 PTGER4 (0.58) KDM4EHPGDEGFRFLT1FLT4
SCHEMBL473470 0.71 KDM4E (0.46) KDM4EHPGDPOLBKMT2A
SCHEMBL1412654 0.71 POLB (0.71) KDM4EHPGDEGFRFLT1FLT4
SCHEMBL209632 0.69 DHFR (0.66) KDM4EHPGDPOLBPTGS2PTGS1
SCHEMBL10931933 0.69 CA2 (0.60) KDM4EHPGDEGFRFLT1FLT4
SCHEMBL453442 0.69 CA2 (0.60) KDM4EHPGDEGFRFLT1FLT4
SCHEMBL8721449 0.69 KDM4E (0.64) KDM4EHPGDEGFRFLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1603893-B1 EP4 RECEPTOR ANTAGONISTS ASTERAND UK LTD (GB) 2008-05-21 EP claimed
US-7858644-B2 EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2010-12-28 US disclosed
US-20090143437-A1 EP4 RECEPTOR ANTAGONISTS ASTERAND UK LIMITED (GB) 2009-06-04 US disclosed
US-7528157-B2 EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2009-05-05 US disclosed
US-7507754-B2 EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2009-03-24 US disclosed
EP-1603893-B1 EP4 RECEPTOR ANTAGONISTS ASTERAND UK LTD (GB) 2008-05-21 EP disclosed
US-20080039502-A1 EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2008-02-14 US disclosed
US-20070123575-A1 EP4 RECEPTOR ANTAGONISTS ASTERAND UK ACQUISITION LIMITED (GB) 2007-05-31 US disclosed
US-7196089-B2 EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2007-03-27 US disclosed
EP-1603893-A1 EP4 RECEPTOR ANTAGONISTS Pharmagene Laboratories Ltd (GB) 2005-12-14 EP disclosed
US-20040192767-A1 EP4 receptor antagonists ASTERAND UK ACQUISITION LIMITED (GB) 2004-09-30 US disclosed
WO-2004067524-A1 EP4 RECEPTOR ANTAGONISTS PHARMAGENE LABORATORIES LIMITED (GB) 2004-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143437-A1 EP4 RECEPTOR ANTAGONISTS PTGER4, NR4A1, NR4A2 KDM4E 1843/4885HPGD 618/4885EGFR 366/4885
US-20040192767-A1 EP4 receptor antagonists PTGER4, PTGER1, NR4A1 KDM4E 1072/4885HPGD 621/4885EGFR 422/4885
US-20070123575-A1 EP4 RECEPTOR ANTAGONISTS PTGER4, NR4A1, PTGER1 KDM4E 1890/4885HPGD 628/4885EGFR 368/4885
US-20080039502-A1 EP4 receptor antagonists PTGER4, NR4A1, PTGER1 KDM4E 2022/4885HPGD 645/4885EGFR 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.